Literature DB >> 14642017

Quetiapine treatment of children and adolescents with Tourette's disorder.

Nahit Motavali Mukaddes1, Osman Abali.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the short-term safety and effectiveness of quetiapine in the treatment of children and adolescents with Tourette's disorder.
METHODS: This was an 8-week, open-label trial that included 12 subjects with a mean age of 11.4 +/- 2.4 years. The subjects were seen every week throughout the study.
RESULTS: Clinical responses, as measured by the Turkish version of the Yale Global Tic Severity Scale, revealed a statistically significant reduction in tic scores ranging from 30-100%. Mean dose of quetiapine at the end of the study was 72.9 +/- 22.5 mg/day. Three subjects complained of sedation in the first week of treatment.
CONCLUSIONS: The favorable results of this open-label study should be interpreted with caution due to the uncontrolled nature of the study. Spontaneous waxing and waning of symptoms should also be considered. Further controlled studies are required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642017     DOI: 10.1089/104454603322572624

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  21 in total

Review 1.  Emerging treatments for Tourette's disorder.

Authors:  Michael H Bloch
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

Review 2.  Updates in medical and surgical therapies for Tourette syndrome.

Authors:  Irene A Malaty; Umer Akbar
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

3.  Clinical effectiveness of quetiapine in children and adolescents with Tourette's syndrome : a retrospective case-note survey.

Authors:  Mazlum Copur; Baki Arpaci; Turkay Demir; Halis Narin
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 4.  Use of quetiapine in children and adolescents.

Authors:  Gabriele Masi; Annarita Milone; Stefania Veltri; Raffaella Iuliano; Chiara Pfanner; Simone Pisano
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

5.  Tourette's Disorder.

Authors:  Gholson J Lyon; David Shprecher; Barbara Coffey; Roger Kurlan
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

6.  Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: implications for predictive validity and Tourette Syndrome.

Authors:  Neal R Swerdlow; Michele J Bongiovanni; Laura Tochen; Jody M Shoemaker
Journal:  Psychopharmacology (Berl)       Date:  2006-04-01       Impact factor: 4.530

7.  Psychopharmacology of tic disorders.

Authors:  Myriam Srour; Paul Lespérance; Francois Richer; Sylvain Chouinard
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2008-08

Review 8.  The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.

Authors:  Cathy L Budman
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

9.  Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.

Authors:  Zainab Al-Dhaher; Sandeep Kapoor; Ema Saito; Scott Krakower; Lisa David; Theodore Ake; John M Kane; Christoph U Correll; Maren Carbon
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-04-19       Impact factor: 2.576

10.  Aripiprazole for the treatment of Tourette's disorder.

Authors:  Prasad R Padala; S Faiz Qadri; Vishal Madaan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.